ITI-5000

ITI-5000 is a self-amplifying RNA (saRNA) therapeutic vaccine under preclinical development by Immunomic Therapeutics. It is designed as an immunostimulant targeting selected antigens for the treatment of triple negative breast cancer (TNBC). The vaccine leverages saRNA technology to induce a robust immune response, aiming to stimulate both cytotoxic and helper T cell activity against tumor cells. The platform likely incorporates Immunomic’s proprietary LAMP (Lysosomal Associated Membrane Protein) or UNITE technology, which enhances antigen presentation via MHC-II pathways and promotes broad immune activation[1][2][4].

Other names

ITI-5000 TNBC VaccineITI5000 TNBC VaccineITI 5000 TNBC VaccineITI-5000 saRNA VaccineITI5000 saRNA VaccineITI 5000 saRNA Vaccine